Activation of liver FXR has shown potential in improving metabolic diseases by inhibiting lipogenesis and glycogenesis, making FXR agonists a promising new target for the treatment of conditions such as obesity and diabetes. The gene discussed is NR1H4; the disease is obesity due to melanocortin 4 receptor deficiency.